Sang Hwan Seo

Company: International Vaccine Institute (IVI)

Job title: Senior Scientist - Research & Lab Manager

Bio:

Dr. Sang Hwan Seo is the Director at the International Vaccine Institute (IVI) and Adjunct Professor at Yonsei University College of Medicine. Since joining the IVI in 2018, Dr. Seo has led multiple vaccine development programs and played a central role in establishing immunological assay platforms to support preclinical as well as clinical-stage research. He has directed the development of vaccine candidates against hepatitis A virus and human adenovirus type 55 and has overseen immunoprofiling studies in both animal models and human clinical trials, with a particular focus on T cell responses and cytokine signatures. Dr. Seo supervises the validation and implementation of key immunoassays?including the focus reduction neutralization test (FRNT), ELISpot, and multiplex cytokine assays using flow cytometry?in compliance with Good Clinical Laboratory Practice (GCLP) standards. These assays are critical for supporting international phase 1?3 clinical trials. He has contributed to the clinical evaluation of COVID-19 vaccines, including SKYCovione, and participated in the development of WHO International Standards for antibodies against MERS-CoV, SARS-CoV-2, and SFTSV. Currently, Dr. Seo is leading a project to develop a decentralized and rapid mRNA vaccine production platform, aimed at strengthening global pandemic preparedness for future threats, including Disease X. Dr. Seo currently serves on the review board of the Korea Preclinical Evaluation Center and as Deputy Editor of Clinical and Experimental Vaccine Research, the official journal of the Korea Vaccine Society and Editor of Journal of Bacteriology and Virology, the official journal of the Korea Society of Virology.

Seminars:

Building a Decentralized & Accelerated mRNA Vaccine Production System (DeCAFx) for Pandemic Preparedness 9:30 am

DeCAFx, led by IVI, is a decentralized, modular mRNA manufacturing platform for rapid, regional pandemic response Collaborating globally on mRNA R&D, including vaccines for Lassa and Rift Valley fevers, saRNA, and novel delivery methods Aligning with CEPI’s 100 Days Mission, DeCAFx aims to enable vaccine rollout within weeks of pathogen detectionRead more

day: Day Two